Deok-gyu Kim, CEO of specialized pharmaceutical manufacturer Jeroncellvein, announced on the 20th that he won the '2025 Global New Korean Award' in the medical category at the '2025 Outstanding National Assembly Member/Local Government Award and Global New Korean Award Ceremony.'
This award ceremony, organized by the "2025 Outstanding National Assembly Member and Local Government Legislator Award & Global New Korean Award" Selection Committee, recognizes individuals who have contributed to the development of the nation and society and have contributed to the advancement of various fields based on their expertise. CEO Kim Deok-gyu was selected as the recipient in recognition of his research achievements in the field of biotechnology.
CEO Kim developed Prism Technology (Prism-T), the world's first patented technology for the uniform production of low-molecular-weight polydeoxyribonucleotides (PDRN), securing the technology to produce uniformly sized nucleic acid fragments. This technology is being utilized in various medical fields, including regenerative medicine, dermatology, and dentistry.
Along with this award, he also received a commendation from the National Assembly's Political Affairs Committee, Kang Min-guk, in recognition of his contributions to the development of the medical and bio industries.
CEO Kim Deok-gyu said, “Jeroncellbein is growing into a leading global biotechnology company by producing PDRN based on its unrivaled technological prowess,” and added, “We plan to continue specialized research and development through collaboration with researchers and medical professionals at home and abroad, and expand our sales network in global markets such as the Americas, Europe, and Asia.”
He also added, “I am delighted that this award recognizes the contributions our research has made to the advancement of the medical and bio industries,” and “We will continue to dedicate ourselves to research and development to promote national health and advance the global healthcare industry.”
- See more related articles
You must be logged in to post a comment.